28.10.2013 19:25:00

Cegedim: the Third Quarter Benefited from Orders Postponed in Q2, as Announced.

Regulatory News:

Cegedim, a global technology and services company specializing in the healthcare field, generated like-for-like* consolidated revenue growth of 4.7% and growth of 1.7% on a reported basis to €211.0 million. Over the first nine months, revenues come to €648.2 million, down 1.9% on a reported basis and 0.5% like for like*.

As announced, the Group’s third quarter performance benefited from the postponement of several orders in June at both the CRM and strategic data division and the Healthcare professionals division; for its part, the Insurance and services division continued to step up its growth over the quarter.

All of the divisions contributed to the like-for-like* revenue growth over the third quarter. Over the first nine months, like-for-like* growth at the Healthcare professionals and Insurance and services divisions nearly offset the decline at the CRM and strategic data division.

Having made up the lost ground, as expected, the Group still expects stable revenues in 2013 and a 50 basis point improvement in its operating margin from continuing operations. The Group has significant growth opportunities at all of its divisions.

Amid these tough conditions, Cegedim continues to prioritize innovation and debt reduction, and has maintained its cost-containment efforts.

  • The change in revenues per division for the 3rd quarter is as follows:
                         
€ thousands       3rd quarter 2013       3rd quarter 2012       Q3 2013/2012 change
                  Reported       L-f-L*
CRM and strategic data 108,106 111,113 (2.7%)       1.7%
Healthcare professionals 65,292 62,623 4.3% 6.4%
Insurance and services       37,617       33,848       11.1%       11.1%
Group       211,014       207,584       1.7%       4.7%
 

* at constant scope and exchange rates

In the third quarter of 2013, Cegedim generated consolidated revenues of €211.0 million, up 1.7% on a reported basis and 4.7% like for like* compared with the same period in 2012. Acquisitions had a marginal impact, and the currency impact was negative 3.1%.

  • The change in revenues per division over 9 months is as follows:
                         
€ thousands       9M 2013       9M 2012       9M 2013/2012 change
                  Reported       L-f-L*
CRM and strategic data 322,732 348,310 (7.3%)       (4.2%)
Healthcare professionals 210,852 205,768 2.5% 1.9%
Insurance and services       114,659       106,780       7.4%       7.4%
Group       648,243       660,858       (1.9%)       (0.5%)
 

Over the first nine months of 2013, Cegedim generated consolidated revenues of €648.2 million, down 1.9% on a reported basis and 0.5% like for like* compared with the same period in 2012. The net impact of acquisitions and divestments (sale of Pharmapost and acquisition of ASP Line) was a positive 0.3%, whereas currencies had a negative impact of 1.7%.

Analysis of business trends by division

  • CRM and strategic data

In the third quarter of 2013, division revenues totaled €108.1 million, down 2.7% on a reported basis. Currencies had a negative impact on revenues of 4.5%, whereas scope effects had a marginal impact. Like-for-like* revenues rose 1.7% over the period.

Nine-month 2013 revenues fell 4.2% on a like-for-like* basis compared with the same period in 2012. Scope effects and currencies made negative contributions of 0.5% and 2.6% respectively.

The CRM and strategic data division represented 50% of the Group’s consolidated revenues, compared with 53% in the year-earlier period.

Growth in the third quarter was attributable to:

  • Catching up on a significant portion of the market research studies postponed in June;
  • The start-up of several new CRM projects, despite the pharmaceutical industry’s changing model;
  • Robust growth in offers linked to the OneKey database, notably in China;
  • The French "Sunshine Act” taking effect, which will entail certain reporting obligations from October 1, including the release of marketing expenses per healthcare professionals. This positive effect is likely to increase in the next quarter.

The Group continues to pursue its investment policy, which will result in the launch of new products and services in the months ahead.

Management is confident that the second half of 2013 will be more dynamic than in 2012 in terms of order book, new product launches, "Compliance” offerings ramp-up and catching up on market research studies.

  • Healthcare Professionals

In the third quarter of 2013, division revenues came to €65.3 million, up 4.3% on a reported basis. There was no impact from acquisitions or divestments in Q3. Currencies had a negative impact of 2.1%. Like-for-like* revenues rose 6.4% over the period.

Like-for-like* revenues over the first nine months of 2013 grew by 1.9%. Acquisitions and divestments had a positive impact of 1.7%, whereas currencies had a negative impact of 1.2%.

The Healthcare professionals division represented 32% of consolidated Group revenues, compared with 31% in the year-earlier period.

Computerization activities for doctors, physical therapists and nurses are developing nicely in Europe, particularly in France, where healthcare professional software design orders made up lost ground, as expected.

This increase was partly offset by wait-and-see attitude of French pharmacists, notably following negotiations of the healthcare system financing impacting their wages. The UK market was affected by a demanding comparison caused by strong launch of e-prescriptions in early-2012.

Management remains confident that it will meet its 2013 targets.

  • Insurance and services

In the third quarter of 2013, division revenues came to €37.6 million, up 11.1% on a reported basis and like for like*. Currencies had virtually no impact, and there were no acquisitions or divestments.

Over the first nine months of 2013, sector revenues grew by 7.4% on a reported basis and like for like* compared with the same period in 2012.

The Insurance and services division represented 18% of consolidated Group revenues compared with 16% in the year-earlier period.

Like-for-like growth gained speed at the division, at 11.1% in Q3 following respective performances of 3.9% and 7.4% in Q1 and Q2. Furthermore, all of the division’s activities contributed to the growth:

  • Cegedim Assurances, the leading supplier of software and services to the personal insurance sector, as well as third-party payer flow management solutions, posted significant third-quarter growth;
  • Cegedim SRH, which makes human resources solutions, continues to garner numerous commercial successes, resulting in double-digit growth;
  • Cegedim e-business, specializing in electronic data flow solutions, is experiencing strong growth stemming in part from the ramp-up of SEPA business.

Management is very confident that it will meet its 2013 targets.

3rd quarter highlights

To the best of the company’s knowledge, there were no events or changes of the sort to significantly alter the Group’s financial situation during the period.

Cegedim is proud to welcome new Board of Directors member Anne Sophie Herelle, who replaces Nicolas Manardo, permanent representative of Bpifrance. We wish Nicolas Manardo, all the best in his new endeavor.

Significant post-closing transactions and events

To the best of the company’s knowledge, there were no subsequent events or changes of the sort to significantly.

Outlook

Cegedim is still working to rein in costs while continuing to prioritize innovation and debt reduction.

In the absence of any major changes in its market trends, the Group still expects stable revenues and reiterates its target of a 50 basis point improvement in the operating margin from continuing operations for 2013.

Financial calendar

The Group will hold a conference call on October 28th, 2013, at 6:15 pm in English (Paris time). The call will be hosted by Jan Eryk Umiastowski, Cegedim Chief Investment Officer and Head of Investor Relations.

A presentation of Cegedim 2013 Q3 Revenue will also be available on the website: http://www.cegedim.com/finance/documentation/Pages/presentations.aspx

Contact numbers:

     

No Access Code
Required

France: +33 (0)1 70 77 09 39
US : +1 866 907 5923
UK and others: +44 (0)20 3367 9455

 

  • November 28, 2013 (after the stock market closes)
    2013 Q3 Results release
  • December 16, 2013 from 2:30pm to 5:00pm (welcome coffee at 2:00pm)
    4th Cegedim Investor Summit
    Cegedim Auditorium - 17 rue de l’Ancienne Mairie - Boulogne Billancourt

Additional information

Complete financial information is available on our website: www.cegedim.com/finance.

A presentation on Cegedim’s third quarter revenues is also available on the website.

Appendices

  • Revenues by division and by quarter#:

# Figures rounded to the nearest unit

* at constant scope and exchange rates

Year 2013

                                         
€ thousands       Q1       Q2       Q3       Q4       Total
CRM and strategic data       104,641       109,985       108,106             322,732
Healthcare professionals 71,032 74,528 65,292 210,852
Insurance and services       37,192       39,850       37,617               114,659
Group       212,865       224,363       211,014               648,243
 

Year 2012

                                         
€ thousands       Q1       Q2       Q3       Q4       Total
CRM and strategic data       111,092       126,105       111,113       139,836       488,145
Healthcare professionals 67,296 75,848 62,623 76,828 282,595
Insurance and services       35,817       37,115       33,848       44,253       151,033
Group       214,205       239,068       207,584       260,916       921,773
 
  • 9 months 2013 revenues by division and by region are as follows:
                                 
        France       EMEA ex France       Americas       APAC
CRM and strategic data       33%       35%       23%       9%
Healthcare professionals 70% 26% 4% 0%
Insurance and services       100%       0%       0%       0%
Group       57%       26%       13%       4%
 
  • 9 months 2013 revenues by division and by currency are as follows:
                                 
        Euro       USD       GBP       Others
CRM and strategic data       50%       20%       5%       25%
Healthcare professionals 72% 4% 23% 1%
Insurance and services       99%       -       -       1%
Group       66%       11%       10%       13%
 
  • Glossary

EPS: Earnings Per Share is a specific financial indicator defined by the Group as the net profit (loss) for the period divided by the weighted average of the number of shares in circulation.

Revenue at constant exchange rate: when changes in revenue at constant exchange rate are referred to, it means that the impact of exchange rate fluctuations has been excluded. The term, "at constant exchange rate” covers the fluctuation resulting from applying the exchange rates for the preceding period to the current fiscal year, all other factors remaining equal.

Revenue on a like-for-like basis: the effect of changes in scope is corrected by restating the sales for the previous period as follows:

  • by removing the portion of sales originating in the entity or the rights acquired for a period identical to the period during which they were held to the current period;
  • similarly, when an entity is transferred, the sales for the portion in question in the previous period are eliminated;

Internal growth: internal growth covers growth resulting from the development of an existing contract, particularly due to an increase in rates and/or the volumes distributed or processed, new contracts, acquisitions of assets allocated to a contract or a specific project.

External growth: external growth covers acquisitions during the current fiscal year, as well as those which have had a partial impact on the previous fiscal year, net of sales of entities and/or assets.

EBIT: Earnings Before Interest and Taxes. EBIT corresponds to the net revenue minus operating expenses (such as salaries, social charges, materials, energy, research, services, external services, advertising, etc.). It is the operating income for the Cegedim Group.

EBIT from continuing operations: this is EBIT restated to take account of non-current items, such as losses on tangible and intangible assets, restructuring, etc. It corresponds to the operating income from continuing operations for the Cegedim group.

EBITDA: Earnings before interest, taxes, depreciation and amortization. EBITDA is the term used when amortization or depreciation and revaluations are not taken into account. "D” stands for depreciation of tangible assets (such as buildings, machines or vehicles), while "A” stands for amortization of intangible assets (such as patents, licenses and goodwill). The EBITDA is restated to take account of non-current items, such as losses on tangible and intangible assets, restructuring, etc. It corresponds to the gross operating earnings from continuing operations for the Cegedim Group.

Net Financial Debt: this represents the Company’s net debt (non-current and current financial debt, bank loans, debt restated at amortized cost and interest on loans) net of cash and cash equivalents and excluding revaluation of debt derivatives.

Net bank debt: this represents net financial debt less Cegedim’s subordinated debt to FCB.

Free cash flow: free cash flow is cash generated, net of the cash part of the following items: (i) changes in working capital requirements, (ii) transactions on equity (changes in capital, dividends paid and received), (iii) capital expenditure net of transfers, (iv) net financial interest paid and (v) taxes paid.

Operating margin: Defined as the ratio of EBIT/revenue.

Operating margin from continuing operations: defined as the ratio of EBIT from continuing operations/revenue

           
About Cegedim:

Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, life sciences companies, healthcare professionals and insurance companies. The world leader in life sciences CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs 8,100 people in more than 80 countries and generated revenue of €922 million in 2012. Cegedim SA is listed in Paris (EURONEXT: CGM).

To learn more, please visit: www.cegedim.com

And follow Cegedim on Twitter: @CegedimGroup

Nachrichten zu Cegedim S.A.mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Cegedim S.A.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Cegedim S.A. 11,60 -1,28% Cegedim S.A.